Anal Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ANL017 MIFTS: 48	Anal Squamous Cell Carcinoma Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma ¹² ¹⁵ ⁷³

Epidermoid Anal Carcinoma ¹²

Carcinoma of Anal Margin ⁷³

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:5525

NCIt ⁵⁰ C9161

UMLS ⁷³ C1412036 C0349534

Sources

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : ¹² An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell carcinoma and in situ carcinoma. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Human cytomegalovirus infection and PI3K-Akt signaling pathway. The drugs Immunologic Factors and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and brain, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 164)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	31.2	AKT1 CDKN2A PIK3CA TP53
2	in situ carcinoma	30.3	CDKN2A TP53
3	suppressor of tumorigenicity 3	30.2	CDKN2A TP53
4	cervix carcinoma	30.1	CDKN2A TP53
5	adenocarcinoma	29.2	AKT1 APC CDKN2A MLH1 PIK3CA TP53
6	papilloma	10.2
7	bladder squamous cell carcinoma	10.2	CDKN2A TP53
8	keratinizing squamous cell carcinoma	10.2	CDKN2A TP53
9	spitz nevus	10.2	CDKN2A TP53
10	bladder carcinoma in situ	10.2	CDKN2A TP53
11	vulva squamous cell carcinoma	10.2	CDKN2A TP53
12	scrotal carcinoma	10.2	CDKN2A TP53
13	vulvar disease	10.2	CDKN2A TP53
14	nasal cavity adenocarcinoma	10.2	CDKN2A TP53
15	bartholin's gland disease	10.2	CDKN2A TP53
16	megaesophagus	10.2	CDKN2A TP53
17	glycogen-rich clear cell breast carcinoma	10.2	CDKN2A TP53
18	gastric adenosquamous carcinoma	10.2	CDKN2A TP53
19	anogenital venereal wart	10.2	CDKN2A TP53
20	cervix uteri carcinoma in situ	10.2	CDKN2A TP53
21	uterus carcinoma in situ	10.2	CDKN2A TP53
22	oral leukoplakia	10.2	CDKN2A TP53
23	meningeal melanomatosis	10.2	CDKN2A TP53
24	dedifferentiated liposarcoma	10.2	CDKN2A TP53
25	endocervical adenocarcinoma	10.2	CDKN2A TP53
26	hyperplastic polyposis syndrome	10.2	APC TP53
27	penile disease	10.2	CDKN2A TP53
28	mutyh-associated polyposis	10.2	APC TP53
29	cervix small cell carcinoma	10.2	CDKN2A TP53
30	necrotizing sialometaplasia	10.2	CDKN2A TP53
31	verrucous carcinoma	10.2	CDKN2A TP53
32	basaloid squamous cell carcinoma	10.2	CDKN2A TP53
33	tongue disease	10.2	CDKN2A TP53
34	biliary tract neoplasm	10.2	CDKN2A TP53
35	optic nerve neoplasm	10.2	CDKN2A TP53
36	juvenile pilocytic astrocytoma	10.2	CDKN2A TP53
37	tonsil cancer	10.2	CDKN2A TP53
38	pre-malignant neoplasm	10.2	CDKN2A TP53
39	polyposis syndrome, hereditary mixed, 1	10.2	APC MLH1
40	recessive dystrophic epidermolysis bullosa	10.1	CDKN2A TP53
41	vulva cancer	10.1	CDKN2A TP53
42	adult hepatocellular carcinoma	10.1	PIK3CA TP53
43	squamous cell papilloma	10.1	CDKN2A TP53
44	malignant spiradenoma	10.1	PIK3CA TP53
45	laryngeal disease	10.1	CDKN2A TP53
46	breast squamous cell carcinoma	10.1	PIK3CA TP53
47	richter's syndrome	10.1	MLH1 TP53
48	thyroid lymphoma	10.1	TP53 TP73
49	barrett's adenocarcinoma	10.1	CDKN2A TP53
50	oropharynx cancer	10.1	CDKN2A TP53

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

²⁶ (show all 26)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	10.12	FBXW7
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	10.12	FBXW7
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	10.12	APC
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	10.12	FBXW7
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	10.12	FBXW7 PIK3CA
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	10.12	AKT1 PIK3CA
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-166	10.12	PIK3CA
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	10.12	AKT1 APC FBXW7 PIK3CA
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-183	10.12	FBXW7
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	10.12	PIK3CA
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	10.12	APC
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	10.12	APC
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	10.12	APC
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	10.12	AKT1 PIK3CA
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	10.12	FBXW7
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	10.12	APC PIK3CA
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	10.12	AKT1
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	10.12	FBXW7
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	10.12	AKT1
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	10.12	APC
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-79	10.12	AKT1
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	10.12	AKT1
23	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.62	AKT1 CDKN2A MLH1 TP53 TP73
24	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.62	AKT1 CDKN2A MLH1 TP53 TP73
25	Decreased CDKN1A mRNA expression	GR00389-S-1	9.33	FBXW7 TP53
26	Decreased CDKN1A mRNA expression	GR00389-S-2	9.33	TP53

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

⁴⁶ (show all 19)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.18	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
2	endocrine/exocrine gland	MP:0005379	10.15	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
3	cardiovascular system	MP:0005385	10.13	AKT1 APC CDKN2A FBXW7 PIK3CA TP53
4	homeostasis/metabolism	MP:0005376	10.11	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
5	embryo	MP:0005380	10.1	AKT1 APC CDKN2A FBXW7 PIK3CA TP53
6	immune system	MP:0005387	10.1	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
7	growth/size/body region	MP:0005378	10.08	AKT1 APC CDKN2A FBXW7 PIK3CA TP53
8	hematopoietic system	MP:0005397	10.07	AKT1 APC CDKN2A FBXW7 MLH1 TP53
9	digestive/alimentary	MP:0005381	10.04	APC CDKN2A FBXW7 MLH1 TP53 TP73
10	mortality/aging	MP:0010768	10.03	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
11	integument	MP:0010771	10.02	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
12	neoplasm	MP:0002006	9.97	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
13	nervous system	MP:0003631	9.87	AKT1 APC CDKN2A FBXW7 PIK3CA TP53
14	liver/biliary system	MP:0005370	9.85	AKT1 APC CDKN2A FBXW7 TP53
15	muscle	MP:0005369	9.8	AKT1 APC CDKN2A PIK3CA TP53
16	reproductive system	MP:0005389	9.8	AKT1 APC CDKN2A MLH1 PIK3CA TP53
17	respiratory system	MP:0005388	9.63	AKT1 CDKN2A FBXW7 MLH1 TP53 TP73
18	skeleton	MP:0005390	9.43	AKT1 APC CDKN2A PIK3CA TP53 TP73
19	vision/eye	MP:0005391	9.17	APC CDKN2A FBXW7 MLH1 PIK3CA TP53

Sources

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 45)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Cisplatin

Approved

Phase 3,Phase 2

15663-27-1

2767 441203 84093

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1

51-21-8

3385

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2

33069-62-4

36314

Capecitabine

Approved, Investigational

Phase 3,Phase 2

154361-50-9

60953

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Early Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2

Antimitotic Agents

Phase 3,Phase 2

Albumin-Bound Paclitaxel

Phase 3,Phase 2

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1,Early Phase 1

Mitomycins

Phase 3,Phase 2,Phase 1,Early Phase 1

Alkylating Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2,Phase 1,Early Phase 1

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904 498142

Cetuximab

Approved

Phase 2

205923-56-4

56842117 2333

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 6857599 5310940 9887054

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Valproic Acid

Approved, Investigational

Phase 2

99-66-1

3121

Pembrolizumab

Approved

Phase 2

1374853-91-4

Antibodies, Monoclonal

Phase 2,Phase 1

Antibodies

Phase 2,Phase 1

Immunoglobulins

Phase 2,Phase 1

Psychotropic Drugs

Phase 2

GABA Agents

Phase 2

Neurotransmitter Agents

Phase 2

Tranquilizing Agents

Phase 2

Anticonvulsants

Phase 2

Antimanic Agents

Phase 2

Central Nervous System Depressants

Phase 2

taxane

Phase 2

Cyclophosphamide

Approved, Investigational

Phase 1

6055-19-2, 50-18-0

2907

Nivolumab

Approved

Phase 1

946414-94-4

Fludarabine

Approved

Phase 1

75607-67-9, 21679-14-1

30751

Manganese

Approved, Nutraceutical

Phase 1

7439-96-5

27854

Vaccines

Phase 1

Antineoplastic Agents, Alkylating

Phase 1

Antirheumatic Agents

Phase 1

Dimenhydrinate

Approved

523-87-5

441281

Hydrogen peroxide

Approved, Vet_approved

7722-84-1

784

Ethanol

Approved

64-17-5

702

Pharmaceutical Solutions

Interventional clinical trials:

(show all 43)

#	Name	Status	NCT ID	Phase	Drugs
1	Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV	Withdrawn	NCT01663558	Phase 4	imiquimod
2	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Unknown status	NCT00003652	Phase 3	cisplatin;fluorouracil
3	Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00003596	Phase 3	cisplatin;fluorouracil;mitomycin C
4	Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer	Completed	NCT00025090	Phase 3	cisplatin;fluorouracil;mitomycin C
5	Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy	Recruiting	NCT02369939	Phase 3	Mitomycin C;5-Fluorouracil
6	Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients	Enrolling by invitation	NCT02526953	Phase 3	Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
7	Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer	Terminated	NCT00068744	Phase 2, Phase 3	cisplatin;fluorouracil;mitomycin C
8	International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel	Unknown status	NCT02051868	Phase 2	Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
9	Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer	Unknown status	NCT00955240	Phase 2	cisplatin;fluorouracil
10	Vectibix for the Treatment of Anal Cancer	Completed	NCT01285778	Phase 2	panitumumab, mytomicin C, 5-FU, radiation
11	Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Completed	NCT00324415	Phase 2	cisplatin;fluorouracil
12	Oral Rigosertib for Squamous Cell Carcinoma	Completed	NCT01807546	Phase 2	rigosertib
13	Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer	Completed	NCT00423293	Phase 2	fluorouracil;mitomycin C
14	Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00093379	Phase 2	Capecitabine;Oxaliplatin
15	A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma	Recruiting	NCT03519295	Phase 2	MPDL3280A;mDCF
16	Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection	Recruiting	NCT02437851	Phase 2
17	Avelumab With Valproic Acid in Virus-associated Cancer	Recruiting	NCT03357757	Phase 2	Valproic Acid
18	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)	Recruiting	NCT02628067	Phase 2
19	A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	Recruiting	NCT02797964	Phase 1, Phase 2	SRA737
20	Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus	Active, not recruiting	NCT01581840	Phase 1, Phase 2	radiochemotherapy;Panitumumab
21	Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma	Active, not recruiting	NCT02402842	Phase 2	Docetaxel, Cisplatin and 5-Fluorouracil
22	Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer	Active, not recruiting	NCT00316888	Phase 2	cisplatin;fluorouracil
23	Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer	Active, not recruiting	NCT02560298	Phase 2	Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
24	A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus	Withdrawn	NCT02857608	Phase 2	Lymphoseek
25	A Phase 1 Study in Participants With Advanced Cancer	Completed	NCT01115790	Phase 1	Prexasertib
26	Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.	Completed	NCT00423254	Phase 1
27	Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer	Recruiting	NCT03386500	Phase 1	BMX-001
28	HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA	Recruiting	NCT02379520	Phase 1	Cytoxan;Fludarabine
29	Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Recruiting	NCT02408861	Phase 1
30	ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy	Completed	NCT02145416
31	Molecular Biology of Anal Cancer in HIV-Positive Patients	Completed	NCT00952874
32	Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor?	Completed	NCT03469596
33	Anal Dysplasia in Patients With Inflammatory Bowel Disease	Completed	NCT01653054	Not Applicable
34	OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer	Completed	NCT00900302
35	Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients	Recruiting	NCT01877135
36	Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III)	Recruiting	NCT03241680	Not Applicable
37	Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men	Recruiting	NCT02816879	Not Applicable
38	Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer	Recruiting	NCT02140021	Not Applicable
39	Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma	Active, not recruiting	NCT01858025	Early Phase 1	5-fluorouracil;Mitomycin-C
40	Seville Cohort of People Living With HIV at Risk for Anal Cancer	Enrolling by invitation	NCT03713229
41	Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.	Not yet recruiting	NCT03061435	Not Applicable
42	Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays	Terminated	NCT02407561
43	Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer	Withdrawn	NCT02162641

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Sources

Genetic Tests for Anal Squamous Cell Carcinoma

Sources

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

⁴¹

Cervix, Lung, Brain, Bone, Breast, Pancreas, Thyroid

Sources

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 110)

#	Title	Authors	Year
1	Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )	Aldersley J...Gabuzda D	2019
2	Distinguishing Anal Squamous Cell Carcinoma and Rectal Squamous Cell Carcinoma in Secondary Data Sets. ( 29420432 )	Leeds I.L....Fang S.H.	2018
3	Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. ( 29337772 )	Guerra G.R....Heriot A.G.	2018
4	Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated? ( 29514401 )	Thompson S.R....Goldstein D.	2018
5	Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. ( 29339717 )	Reali C....Hompes R.	2018
6	Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. ( 29296096 )	Zhao Y.J....Pan Z.Z.	2018
7	Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. ( 28975226 )		2018
8	HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma. ( 29466950 )		2018
9	ASO Author Reflections: The Role of Tumor Size in the Prognosis of Anal Squamous Cell Carcinoma: A Validation on the New American Joint Committee on Cancer Subclassification of Stage IIA and B. ( 30367300 )	Goffredo P...Hassan I	2018
10	Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. ( 30415990 )	Guren MG...M?ller B	2018
11	Radiation Therapy for Anal Squamous Cell Carcinoma: A Retrospective Multicenter Study. ( 30504412 )	Koh HK...Kim MS	2018
12	Multiple primary malignancies in patients with anal squamous cell carcinoma. ( 30505585 )	Li D...Jabbour SK	2018
13	Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 29122359 )	R?del F...Yuan J	2018
14	Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. ( 29416628 )	Cacheux W...Li?vre A	2018
15	The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. ( 29487716 )	Sun G...Zhao E	2018
16	Anal squamous cell carcinoma - State of the art management and future perspectives. ( 29494827 )	Martin D...Fokas E	2018
17	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. ( 30042063 )	Kim S...Borg C	2018
18	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. ( 30054279 )	Cabel L...Cacheux W	2018
19	Oestrogen receptor can be expressed by normal and dysplastic anal squamous epithelia but only rarely by anal squamous cell carcinoma. ( 30062743 )	Wong NACS	2018
20	Anal squamous cell carcinoma: are we improving outcomes? ( 30159994 )	Mackowski A...Platell C	2018
21	Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. ( 30194195 )	Heinze C...Powerski MJ	2018
22	Anal Squamous Cell Carcinoma in a Patient with Myasthenia Gravis: Is Immunosuppression the Main Underlying Etiology? ( 29348988 )	Masab M....Saif M.W.	2017
23	Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. ( 29137429 )	Wan Z....Li J.	2017
24	The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. ( 29315288 )	Johnson B....Eng C.	2017
25	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. ( 28334399 )	Yanik E.L....Taube J.M.	2017
26	Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). ( 28841909 )	Kim S....Borg C.	2017
27	High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role. ( 28453691 )	Ravenda P.S....Fazio N.	2017
28	Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. ( 29299360 )	Jhaveri J....Landry J.C.	2017
29	Recurrent anal squamous cell carcinoma in a patient who refuses end colostomy: What to do? ( 29100741 )	Tremblay J.F....Pocard M.	2017
30	Coincidence or not? A rare case of rectal leiomyosarcoma amidst incidental findings of anal squamous cell carcinoma: case presentation and literature review. ( 28959428 )		2017
31	Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 28893059 )		2017
32	The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. ( 28258896 )		2017
33	Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. ( 29035618 )		2017
34	Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. ( 28747781 )		2017
35	Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 25984929 )	Julie D.A....Goodman K.A.	2016
36	A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. ( 27125703 )	Daniel F....Ziade N.	2016
37	A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. ( 27284490 )	Gnanajothy R....Peterson L.L.	2016
38	Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. ( 26818664 )	Kotze P.G....Zacharias P.	2016
39	A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. ( 26961789 )	Kim S.S....Ko A.H.	2016
40	Chemoradiotherapy for anal squamous cell carcinoma. ( 27118047 )	Houlihan O.A....O'Neill B.D.	2016
41	Anal squamous cell carcinoma in Crohn's disease. ( 27773118 )		2016
42	Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. ( 27052656 )		2016
43	Metastatic rectal adenocarcinoma and anal squamous cell carcinoma masquerading as vulvar lymphangioma circumscriptum. ( 27616148 )		2016
44	Genomic evolution after chemoradiotherapy in anal squamous cell carcinoma. ( 27852700 )		2016
45	Anal squamous cell carcinoma in chronic severe perianal Crohn's disease. ( 25702309 )	Arana de la Torre M....Colina Alonso A.	2015
46	Grade 4 radiation dermatitis presenting with full-thickness ulcerations of the groin after radiation therapy for anal squamous cell carcinoma (SCC): An example of the &quot;bolus effect&quot; of radiation therapy. ( 27051789 )	Blackcloud P....Grossman M.E.	2015
47	A tumor control probability model for anal squamous cell carcinoma. ( 26243680 )	Muirhead R....Hawkins M.A.	2015
48	Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma. ( 26287957 )	Hu W.H....Ramamoorthy S.L.	2015
49	Concomitant Chemoradiotherapy with Cisplatin Plus 5-Fluorouracil for Anal Squamous Cell Carcinoma. ( 25810165 )	El-Hadaad H.A....Roshdy S.	2015
50	Human papillomavirus DNA load and p16(INK4a) expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 24839133 )	RAPdel F....RAPdel C.	2015

Sources

Genes for Anal Squamous Cell Carcinoma

Genes related to Anal Squamous Cell Carcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	22.91	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	TP53	Tumor Protein P53	Protein Coding	21.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	21	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	19.99	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	APC	APC, WNT Signaling Pathway Regulator	Protein Coding	17.32	GeneCards inferred via : Publications (show sections)
6	MLH1	MutL Homolog 1	Protein Coding	17.32	GeneCards inferred via : Publications (show sections)
7	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	16.98	GeneCards inferred via : Publications (show sections)
8	TP73	Tumor Protein P73	Protein Coding	16.98	GeneCards inferred via : Publications (show sections)

Sources

Variations for Anal Squamous Cell Carcinoma

Sources

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Sources

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 76)

#	Super pathways	Score	Top Affiliating Genes
1	Human cytomegalovirus infection ³⁷ Show member pathways Hepatitis B ³⁷ Human immunodeficiency virus 1 infection ³⁷ Kaposi sarcoma-associated herpesvirus infection ³⁷	12.92	AKT1 CDKN2A PIK3CA TP53
2	PI3K-Akt signaling pathway ³⁷ Show member pathways Human papillomavirus infection ³⁷	12.85	AKT1 APC PIK3CA TP53
3	Regulation of TP53 Activity ⁶⁶ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁶ Regulation of TP53 Activity through Methylation ⁶⁶ Regulation of TP53 Activity through Phosphorylation ⁶⁶ Transcriptional Regulation by TP53 ⁶⁶	12.78	AKT1 CDKN2A MLH1 TP53 TP73
4	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ¹ Apoptosis ³⁷ Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathways ⁶⁵ Death Receptor Signaling ⁶⁷	12.65	AKT1 CDKN2A PIK3CA TP53 TP73
5	Influenza A ³⁷ Show member pathways Herpes simplex infection ³⁷ Measles ³⁷	12.64	AKT1 PIK3CA TP53 TP73
6	Glioma ³⁷ Show member pathways EGFR tyrosine kinase inhibitor resistance ³⁷ Endocrine resistance ³⁷ Melanoma ³⁷ Non-small cell lung cancer ³⁷ Signaling Pathways in Glioblastoma ¹	12.61	AKT1 CDKN2A PIK3CA TP53
7	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.59	AKT1 APC CDKN2A MLH1 PIK3CA TP53
8	Development HGF signaling pathway ²² Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development Neurotrophin family signaling ²² MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ Neurotrophin signaling pathway ³⁷ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.54	AKT1 APC PIK3CA TP53 TP73
9	Pathways in cancer ³⁷	12.52	AKT1 APC CDKN2A MLH1 PIK3CA TP53
10	MicroRNAs in cancer ³⁷	12.38	APC CDKN2A PIK3CA TP53
11	ErbB signaling pathway ¹ ³⁷ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶¹ Renal cell carcinoma ³⁷ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.37	AKT1 PIK3CA TP53
12	DNA Damage ⁴	12.36	CDKN2A MLH1 TP53 TP73
13	mTOR signaling pathway (KEGG) ⁶⁵ Show member pathways mTOR signaling pathway ³⁷	12.35	AKT1 APC PIK3CA TP53
14	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.34	AKT1 PIK3CA TP53
15	AMP-activated Protein Kinase (AMPK) Signaling ¹ Show member pathways AMPK signaling pathway ³⁷ AMPK Signaling Pathway ⁶⁷	12.33	AKT1 PIK3CA TP53
16	WNT Signaling ⁶⁴	12.32	AKT1 APC TP53
17	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.3	AKT1 APC CDKN2A MLH1 PIK3CA TP53
18	Development IGF-1 receptor signaling ²² Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.29	AKT1 PIK3CA TP53
19	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁷	12.27	CDKN2A TP53 TP73
20	Cell cycle ¹ ³⁷	12.25	APC CDKN2A TP53
21	Human T-cell leukemia virus 1 infection ³⁷	12.24	AKT1 APC CDKN2A PIK3CA TP53
22	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.21	AKT1 PIK3CA TP53
23	Epstein-Barr virus infection ³⁷	12.18	AKT1 PIK3CA TP53
24	Proteoglycans in cancer ³⁷	12.17	AKT1 PIK3CA TP53
25	Viral carcinogenesis ³⁷	12.17	CDKN2A PIK3CA TP53
26	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.1	AKT1 PIK3CA TP53
27	mTOR Pathway ⁷² Show member pathways Insulin Pathway ⁷² TGF-beta Pathway ⁷²	12.05	AKT1 PIK3CA TP53
28	Colorectal Cancer Metastasis ⁶⁴	12.05	AKT1 APC MLH1 TP53
29	Cellular senescence (KEGG) ³⁷	12.03	AKT1 CDKN2A PIK3CA TP53
30	Longevity regulating pathway ³⁷ Show member pathways Longevity regulating pathway - multiple species ³⁷	12.01	AKT1 PIK3CA TP53
31	AKT Signaling Pathway ⁶⁷	12	AKT1 PIK3CA TP53
32	Fluid shear stress and atherosclerosis ³⁷	11.97	AKT1 PIK3CA TP53
33	Signaling pathways regulating pluripotency of stem cells ³⁷	11.97	AKT1 APC PIK3CA
34	Hepatitis C ³⁷	11.94	AKT1 PIK3CA TP53
35	Direct p53 effectors ¹	11.92	APC MLH1 TP53 TP73
36	Activation of BH3-only proteins ⁶⁶ Show member pathways Activation of BAD and translocation to mitochondria ⁶⁶ Activation of BIM and translocation to mitochondria ⁶⁶ Activation of BMF and translocation to mitochondria ⁶⁶ Activation of NOXA and translocation to mitochondria ⁶⁶ Activation of PUMA and translocation to mitochondria ⁶⁶ Activation, myristolyation of BID and translocation to mitochondria ⁶⁶ BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members ⁶⁶ Intrinsic Pathway for Apoptosis ⁶⁶	11.9	AKT1 TP53 TP73
37	MAPK Pathway ⁷² Show member pathways Toll-like Receptor Pathway ⁷²	11.9	AKT1 PIK3CA TP53
38	Sphingolipid signaling pathway ³⁷	11.87	AKT1 PIK3CA TP53
39	Thyroid hormone signaling pathway ³⁷	11.86	AKT1 PIK3CA TP53
40	Glioblastoma Multiforme ⁶⁴	11.8	AKT1 APC CDKN2A TP53
41	Small cell lung cancer ³⁷	11.76	AKT1 PIK3CA TP53
42	Regulation of TP53 Expression and Degradation ⁶⁶ Show member pathways Regulation of TP53 Degradation ⁶⁶ Regulation of TP53 Expression ⁶⁶	11.64	AKT1 CDKN2A TP53
43	p75(NTR)-mediated signaling ¹ Show member pathways Ceramide signalling ⁶⁶ NFG and proNGF binds to p75NTR ⁶⁶	11.57	AKT1 PIK3CA TP53
44	Central carbon metabolism in cancer ³⁷	11.56	AKT1 PIK3CA TP53
45	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.52	AKT1 FBXW7 PIK3CA TP53
46	DNA damage_Role of Brca1 and Brca2 in DNA repair ²²	11.45	AKT1 MLH1 TP53
47	Carbohydrate digestion and absorption ³⁷	11.39	AKT1 PIK3CA
48	Deactivation of the beta-catenin transactivating complex ⁶⁶	11.38	AKT1 APC
49	Insulin Pathway ¹	11.38	AKT1 PIK3CA
50	Doxorubicin Pathway, Pharmacokinetics ⁶¹ Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶¹	11.35	MLH1 TP53

Sources

GO Terms for Anal Squamous Cell Carcinoma

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytosol	GO:0005829	9.7	AKT1 APC CDKN2A FBXW7 PIK3CA TP53
2	mitochondrion	GO:0005739	9.35	AKT1 CDKN2A FBXW7 TP53 TP73
3	nucleoplasm	GO:0005654	9.17	AKT1 APC CDKN2A FBXW7 MLH1 TP53

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 24)

#	Name	GO ID	Score	Top Affiliating Genes
1	apoptotic process	GO:0006915	9.86	AKT1 CDKN2A TP53 TP73
2	cytokine-mediated signaling pathway	GO:0019221	9.79	AKT1 PIK3CA TP53
3	cell cycle	GO:0007049	9.78	CDKN2A MLH1 TP53 TP73
4	regulation of apoptotic process	GO:0042981	9.77	AKT1 TP53 TP73
5	positive regulation of transcription, DNA-templated	GO:0045893	9.76	AKT1 CDKN2A TP53 TP73
6	protein destabilization	GO:0031648	9.62	CDKN2A FBXW7
7	negative regulation of Notch signaling pathway	GO:0045746	9.61	AKT1 FBXW7
8	protein kinase B signaling	GO:0043491	9.6	AKT1 PIK3CA
9	protein tetramerization	GO:0051262	9.58	TP53 TP73
10	phosphatidylinositol 3-kinase signaling	GO:0014065	9.58	AKT1 PIK3CA
11	mismatch repair	GO:0006298	9.57	MLH1 TP73
12	intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	GO:0042771	9.55	TP53 TP73
13	cellular response to DNA damage stimulus	GO:0006974	9.55	AKT1 APC MLH1 TP53 TP73
14	positive regulation of cell cycle arrest	GO:0071158	9.54	TP53 TP73
15	negative regulation of cyclin-dependent protein serine/threonine kinase activity	GO:0045736	9.52	APC CDKN2A
16	vasculature development	GO:0001944	9.51	FBXW7 PIK3CA
17	positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway	GO:1900740	9.49	TP53 TP73
18	apoptotic mitochondrial changes	GO:0008637	9.43	AKT1 CDKN2A
19	regulation of signal transduction by p53 class mediator	GO:1901796	9.43	AKT1 TP53 TP73
20	negative regulation of macroautophagy	GO:0016242	9.4	AKT1 PIK3CA
21	replicative senescence	GO:0090399	9.37	CDKN2A TP53
22	anoikis	GO:0043276	9.32	AKT1 PIK3CA
23	cell cycle arrest	GO:0007050	9.26	APC CDKN2A TP53 TP73
24	positive regulation of apoptotic process	GO:0043065	9.02	AKT1 APC CDKN2A TP53 TP73

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ubiquitin protein ligase binding	GO:0031625	9.5	APC FBXW7 TP53
2	identical protein binding	GO:0042802	9.35	AKT1 APC FBXW7 TP53 TP73
3	disordered domain specific binding	GO:0097718	9.26	CDKN2A TP53
4	protein phosphatase 2A binding	GO:0051721	9.16	AKT1 TP53
5	protein kinase binding	GO:0019901	9.02	AKT1 APC CDKN2A TP53 TP73

Sources

Sources for Anal Squamous Cell Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia